Anixa Biosciences, Inc. ANIX
NASDAQ
| 07/31/2026 | 04/30/2026 | 01/31/2026 | 10/31/2025 | 07/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -3.58% | 1.91% | 4.82% | -19.35% | 19.07% |
| Total Depreciation and Amortization | 0.00% | 0.00% | 11.11% | 0.00% | 0.00% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -5.08% | -18.71% | -1.32% | 1.71% | -27.94% |
| Change in Net Operating Assets | 98.96% | 110.93% | -247.07% | 828.05% | -158.57% |
| Cash from Operations | -1.67% | 33.30% | -107.97% | 16.94% | -0.53% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -158.06% | -65.64% | 87.77% | 178.51% | -135.57% |
| Cash from Investing | -158.06% | -65.64% | 87.77% | 178.51% | -135.57% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -25.43% | 4,690.00% | -81.93% | -83.82% | 51,200.00% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 87.26% | -200.00% | 8,927.78% | 114.63% | -823.53% |
| Cash from Financing | 55.00% | -25.88% | 381.43% | -81.86% | 10,616.67% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -12.86% | -123.10% | 220.72% | 39.52% | -148.42% |